Moreover, mesothelioma cells with BAP1 mutations have shown sensitivity to EZH2 inhibition, leading to clinical trials investigating the use of tazemetostat in treating malignant mesothelioma with BAP1 inactivation (NCT02860286).1345. This evidence concerns the gene BAP1 and malignant mesothelioma.